AR and prostate cancer: Examples of selectively targeted mutations to therapeutic agents are anti-androgens in the treatment of prostate cancer, where the androgen receptor incurs a mutation to the targeting ligand binding domain, where now the antagonizing drug functions act as agonists [175,176].